Literature DB >> 25573992

The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura.

Wendy Lim1, Sara K Vesely2, James N George2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25573992      PMCID： PMC4351502          DOI： 10.1182/blood-2014-10-559211

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  28 in total

1.  A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Vickie McDonald; Jamie Cavenagh; Beverley J Hunt; Ian Longair; Hannah Cohen; Samuel J Machin
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

Review 2.  Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature.

Authors:  Huichung T Ling; Joshua J Field; Morey A Blinder
Journal:  Am J Hematol       Date:  2009-07       Impact factor: 10.047

3.  Survival and relapse in patients with thrombotic thrombocytopenic purpura.

Authors:  Johanna A Kremer Hovinga; Sara K Vesely; Deirdra R Terrell; Bernhard Lämmle; James N George
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

4.  Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases.

Authors:  Myrna Pequeño-Luévano; Laura Villarreal-Martínez; José Carlos Jaime-Pérez; Andrés Gómez-de-León; Olga Graciela Cantú-Rodríguez; Oscar González-Llano; David Gómez-Almaguer
Journal:  Hematology       Date:  2013-02-20       Impact factor: 2.269

5.  Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse.

Authors:  J-P Westwood; H Webster; S McGuckin; V McDonald; S J Machin; M Scully
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

6.  Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab.

Authors:  Jens Marcus Chemnitz; Jens Uener; Michael Hallek; Christof Scheid
Journal:  Ann Hematol       Date:  2010-04-27       Impact factor: 3.673

7.  Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab.

Authors:  Jatinder Goyal; Jill Adamski; Jose L O Lima; Marisa B Marques
Journal:  J Clin Apher       Date:  2013-07-16       Impact factor: 2.821

8.  Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child.

Authors:  Somasundaram Jayabose; Julie Dunbar; Theodore S Nowicki; Oya Tugal; Mehmet Fevzi Ozkaynak; Claudio Sandoval
Journal:  Pediatr Hematol Oncol       Date:  2010-05-14       Impact factor: 1.969

9.  Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study.

Authors:  Javier de la Rubia; Federico Moscardó; María J Gómez; Ramón Guardia; Pilar Rodríguez; Ana Sebrango; Concepción Zamora; Guillermo Debén; Rosa Goterris; Rafaela López; Francisco Peña; Misericordia Pujol; Antonio Vidaller; Julio Del Río-Garma; Miguel A Sanz
Journal:  Transfus Apher Sci       Date:  2010-10-12       Impact factor: 1.764

10.  Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.

Authors:  Elena Bresin; Sara Gastoldi; Erica Daina; Daniela Belotti; Enrico Pogliani; Paolo Perseghin; Potito R Scalzulli; Rossella Paolini; Raimondo Marcenò; Giuseppe Remuzzi; Miriam Galbusera
Journal:  Thromb Haemost       Date:  2009-02       Impact factor: 5.249
View more
  22 in total

1.  Thrombotic thrombocytopenic purpura in a new onset lupus patient?

Authors:  Nery Sablón González; Noel Lorenzo; Yanet Parodis; Maria Belen Alonso Ortiz; Melek Kechida; Jose Carlos Rodriguez Perez
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

Review 2.  Thrombotic microangiopathies: a general approach to diagnosis and management.

Authors:  Donald M Arnold; Christopher J Patriquin; Ishac Nazy
Journal:  CMAJ       Date:  2016-10-17       Impact factor: 8.262

Review 3.  The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective.

Authors:  James N George
Journal:  Blood Adv       Date:  2018-06-26

4.  Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Evaren E Page; Johanna A Kremer Hovinga; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2016-09-13       Impact factor: 22.113

Review 5.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

6.  Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases.

Authors:  Xinping Zhou; Xingnong Ye; Yanling Ren; Chen Mei; Liya Ma; Jiansong Huang; Weilai Xu; Juying Wei; Li Ye; Wenyuan Mai; Wenbin Qian; Haitao Meng; Jie Jin; Hongyan Tong
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

Review 7.  Sjögren's syndrome initially presented as thrombotic thrombocytopenic purpura in a male patient: a case report and literature review.

Authors:  Xiaohan Xu; Tienan Zhu; Di Wu; Lu Zhang
Journal:  Clin Rheumatol       Date:  2017-11-13       Impact factor: 2.980

8.  Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.

Authors:  Evaren E Page; Johanna A Kremer Hovinga; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood Adv       Date:  2017-04-06

9.  Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil.

Authors:  F Fioredda; E Cappelli; A Mariani; A Beccaria; E Palmisani; A Grossi; I Ceccherini; R Venè; C Micalizzi; M Calvillo; F Pierri; I Mancini; F Peyvandi; F Corsolini; C Dufour; M Miano
Journal:  Blood Adv       Date:  2019-11-12

10.  Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy.

Authors:  Yoshitaka Miyakawa; Kazunori Imada; Tatsuo Ichinohe; Kenji Nishio; Takayuki Abe; Mitsuru Murata; Yasunori Ueda; Yoshihiro Fujimura; Masanori Matsumoto; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2016-05-17       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.